Coadministration of Anti-Viral Monoclonal Antibodies With Routine Pediatric Vaccines and Implications for Nirsevimab Use: A White Paper
- Susanna Esposito; Bahaa Abu-Raya; Paolo Bonanni; Fabianne Cahn-Sellem; Katie Flanagan; Federico Torres
Access Resources
About
This article explores the use of anti-viral monoclonal antibodies (mAbs) with routine pediatric vaccines, focusing on nirsevimab for RSV prevention. It describes how mAbs can protect infants from infections and highlights the success of palivizumab in preventing severe RSV cases. Nirsevimab shows promise due to its higher potency and longer protection than palivizumab. The paper suggests that coadministration of mAbs like nirsevimab with vaccines is unlikely to interfere with immune responses, supporting their potential inclusion in regular vaccination schedules for better infant health outcomes.
Tags
More like this
The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.